Bansal Himanshu, Verma Poonam, Agrawal Anupama, Leon Jerry, Sundell I Birgitta, Koka Prasad S
Mother Cell, Anupam Hospital, Rudrapur, Uttarakhand, India.
RegennMed Research and Therapeutics, New Delhi, India.
J Stem Cells. 2016;11(1):25-36.
Autism is a neural disorder presenting in the early developmental period, usually in the first 2 years of life. It is characterized by persistent deficits in social communication and social interaction, restricted and repetitive patterns of behavior, interests, or activities, and causes clinically significant impairment in social, occupational, or other important areas of functioning. Cellular therapy is an advanced approach to treat disorders where current therapies do not offer a cure or efficient symptom relief. Herein we present the data of ten autistic patients who were enrolled in this study utilizing stem cells. All patients were scored on ISAA and WeeFIM scales before and at 3, 6, 12 or 24 months following the injection of stem cells. The ISAA scores of the patients improved with the injection, and no adverse effects were noted. We report promising results in this small pilot study using autologous Bone Marrow Aspirate Concentrate (BMAC) injected intrathecally into these ten enrolled autistic patients.
自闭症是一种在发育早期出现的神经障碍，通常在生命的头两年。其特征是社交沟通和社交互动持续存在缺陷、行为、兴趣或活动模式受限且重复，并在社交、职业或其他重要功能领域造成临床上显著的损害。细胞疗法是一种先进的治疗方法，用于治疗目前疗法无法治愈或有效缓解症状的疾病。在此，我们展示了十名自闭症患者的数据，这些患者参与了本研究，接受了干细胞治疗。所有患者在注射干细胞前以及注射后3、6、12或24个月时接受了ISAA和WeeFIM量表评分。患者的ISAA评分随着注射而提高，且未观察到不良反应。我们在这项小型试点研究中报告了有前景的结果，该研究将自体骨髓抽吸浓缩物（BMAC）鞘内注射到这十名参与研究的自闭症患者体内。
